Quantcast

Increasing Use of Ablation to Treat Atrial Fibrillation

January 14, 2009

EP Ablation Catheter Market to grow to over $480 million by 2013, according to Millennium Research Group

WALTHAM, Mass., Jan. 14 /PRNewswire/ — According to Millennium Research Group’s (MRG’s) US Markets for Electrophysiology (EP) Mapping and Ablation Devices 2009 report, an increase in the number of catheter ablation procedures for treating atrial fibrillation (AF) will fuel revenues in the EP ablation catheter market over the next five years. The ablation catheter market will exhibit strong growth from 2008 to 2013, at a compound annual rate of almost 14%, exceeding $480 million by the end of 2013.

With the increased clinical attention AF is generating, market competitors are increasingly targeting their product development efforts towards designing AF-specific catheters. The pending US approval of the first AF-indicated ablation catheter is expected to be the first of many devices to earn this designation.

In November 2008, an FDA advisory panel voted to expand the label for Biosense Webster’s NaviStar ThermoCool radiofrequency ablation catheter to include an indication for AF. Several other manufacturers are also pursuing AF approval for their devices. CryoCath (acquired by Medtronic in Q3 2008) and Ablation Frontiers are developing ablation catheters specifically designed for cardiac anatomy associated with AF.

“A number of leading competitors are developing therapeutic solutions for treating AF safely and effectively,” says Anuk Karunaratne, Senior Analyst at MRG. “Currently, only a small percentage of patients with AF are treated with catheter ablation, but by 2013 this percentage will have tripled, and AF-indicated devices will be in a strong position to gain share of these procedures.”

MRG’s US Markets for Electrophysiology Mapping and Ablation Devices 2009 report provides coverage of key industry competitors, including Biosense Webster, Boston Scientific, GE Healthcare, Siemens Healthcare, St. Jude Medical, and more.

About Atrial Fibrillation

With an estimated prevalence approaching 3.2 million in the US in 2008, AF is the most common clinically significant cardiac arrhythmia. AF causes up to a 30% reduction in cardiac output, leading to shortness of breath and fatigue. AF is also a significant risk factor for stroke because blood pools form in the atria as a result of inefficient pumping, which then increases the likelihood of clot formation.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through published reports, ongoing Marketrack(TM) projects, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

    For more information, contact:

    Amy Krohn
    Millennium Research Group
    416-364-7776 x101
    akrohn@mrg.net

    Elizabeth Marshall
    Decision Resources, Inc.
    781-296-2563
    emarshall@dresources.com

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Millennium Research Group


Source: newswire



comments powered by Disqus